Allergies News and Research

Latest Allergies News and Research

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase Deficiency.

9 May 2013

Viewpoints: Capitol Hill antics on budget; A mom's concern about Plan B decision

Republicans, after berating Democrats for enacting Obamacare and other bills behind closed doors with extra-parliamentary procedures, are insisting that any talks with Democrats be behind closed doors with extra-parliamentary procedures.

9 May 2013

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.

9 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

FDA accepts Merck's BLA for investigational ragweed pollen sublingual allergy immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced that the Biologics License Application for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration.

9 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Study investigates use of sublingual immunotherapy against ragweed allergy

An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal congestion and itchy eyes experienced by ragweed allergy sufferers.

8 May 2013

Swedish researchers report simple habit to protect against allergy development in children

Allergies are very common in industrialized countries. It has been suggested that exposure to harmless bacteria during infancy may be protective against the development of allergy. However, it has been difficult to pinpoint which bacteria a baby should be exposed to, and at what time and by which route this exposure should ideally occur.

8 May 2013

Breast milk might prevent premature babies from deadly intestinal condition

An ingredient that naturally occurs in breast milk might be used to prevent premature babies from developing a deadly intestinal condition that currently is largely incurable, according to researchers at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC in this week's online early edition of the Proceedings of the National Academy of Sciences.

7 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

New report highlights factors that contribute to asthma

There is still no cure for asthma, so for 22 million people in the U.S., this chronic disease continues to be a daily burden no matter where they live. But it's not just air pollution they should be worried about. Factors such as pollen, secondhand smoke – even high rates of poverty, a large uninsured population or a high number of ER visits – can be critical signs that certain cities and states are worse for families with asthma. It is especially true for people with severe asthma.

7 May 2013

Oral drops provide a safe and effective alternative for allergy sufferers

Allergy shots are commonly used to treat children with severe environmental allergies and asthma, but under-the-tongue drops may offer yet another beneficial - and stick-free - option for pediatric allergy sufferers, according to a Johns Hopkins Children's Center review of existing scientific evidence.

6 May 2013

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.

4 May 2013

Study: Chalk may cause allergy and asthma symptoms in students with milk allergy

Many of today's school teachers opt for dustless chalk to keep hands and classrooms clean. But according to a study published in the May issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), this choice in chalk may cause allergy and asthma symptoms in students that have a milk allergy.

3 May 2013

Atopy’s immunologic properties change with age in asthma

The strength of interaction between atopy and elevated eosinophil levels in asthma decreases with age, a study finds.

30 Apr 2013

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Glide Pharma® today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfēnex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.

30 Apr 2013

New patch therapy: A breakthrough for peanut allergy sufferers

The Food Allergy Center at Rady Children's Hospital-San Diego is one of eight hospitals in the United States participating in an international peanut allergy desensitization study.

30 Apr 2013

Children born outside U.S. have lower prevalence of allergic disease

A study by Jonathan I. Silverberg, M.D., Ph.D., M.P.H., of St. Luke's—Roosevelt Hospital Center, New York, and colleagues suggests children living the in the United States but born outside the U.S. have a lower prevalence of allergic disease that increases after residing in the United States for one decade.

30 Apr 2013

Overweight exacerbates air pollution symptoms in childhood asthma

Children with asthma who are overweight are more likely to experience symptoms after exposure to indoor air pollution than normal-weight asthmatic children, show study findings.

29 Apr 2013

UAB expert offers simple strategies to tackle summer allergy season

Sneezing, wheezing and coughing are just some of the symptoms that seasonal allergies can stir up. One sinus expert at the University of Alabama at Birmingham said despite a late spring, the summer allergy season will be strong.

29 Apr 2013

Allergies News and Research

Latest Allergies News and Research

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Viewpoints: Capitol Hill antics on budget; A mom's concern about Plan B decision

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

FDA accepts Merck's BLA for investigational ragweed pollen sublingual allergy immunotherapy tablet

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Study investigates use of sublingual immunotherapy against ragweed allergy

Swedish researchers report simple habit to protect against allergy development in children

Breast milk might prevent premature babies from deadly intestinal condition

Rigel reports net loss of $25.6 million in first quarter 2013

New report highlights factors that contribute to asthma

Oral drops provide a safe and effective alternative for allergy sufferers

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Study: Chalk may cause allergy and asthma symptoms in students with milk allergy

Atopy’s immunologic properties change with age in asthma

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

New patch therapy: A breakthrough for peanut allergy sufferers

Children born outside U.S. have lower prevalence of allergic disease

Overweight exacerbates air pollution symptoms in childhood asthma

UAB expert offers simple strategies to tackle summer allergy season

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Allergies News and Research

Latest Allergies News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in